Article
The trajectory of prognostication and risk stratification for patients with myelodysplastic syndromes.
Blood - 28 Dec 2023
DeZern Amy E, Greenberg Peter L
Abstract excerpt
ABSTRACT: Risk stratification and prognostication are crucial for the appropriate management of patients with myelodysplastic syndromes (MDSs) or myelodysplastic neoplasms, for whom the expected survival can vary from a few months to >10 years. For the past 5 decades, patients with MDS have been classified into higher-risk vs lower-risk disease phenotypes using sequentially developed clinical prognostic scoring...
Topics
- Humans
- Prognosis
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
- Phenotype
- Risk Assessment